New 'Smart Bomb' drug seeks to attack advanced prostate cancer
NCT ID NCT07258407
Summary
This study is testing a new drug called TD001 for men with advanced prostate cancer that has spread and is no longer responding to standard hormone treatments. The drug is designed to target and deliver a toxic payload directly to prostate cancer cells. The main goals are to find the safest and most effective dose and to see if the drug can help control the cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC CASTRATION-RESISTANT PROSTATIC CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Hôpital Paris Saint Joseph
RECRUITINGParis, 75014, France
-
Institut Bergonié
RECRUITINGBordeaux, 33076, France
-
Institut Gustave Roussy
RECRUITINGVillejuif, 94805, France
-
Yale University, Yale Cancer Center
NOT_YET_RECRUITINGNew Haven, Connecticut, 06520, United States
Conditions
Explore the condition pages connected to this study.